FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB A	OMB APPROVAL					
OMB Number:	OMB Number: 3235-0104					
Estimated avera	age burden					
hours per respo	onse: 0.5					

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RAYNOR DANIEL		F (I	Date of Event Requiring Staten Month/Day/Year	nent	3. Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ANIP]							
(Last) C/O ANI PHA 210 MAIN ST	(First)	(Middle)	.,,12,2010			tionship of Reporting Perso all applicable) Director Officer (give title	on(s) to Issue 10% Own Other (spe	er	(Mon	Amendment, Da hth/Day/Year) 6/2013	ate of Original Filed	
(Street) BAUDETTE (City)		56623 (Zip)				below)	below)			cable Line) Form filed b	/Group Filing (Check y One Reporting Person y More than One erson	
		Ţ	able I - Non	-Derivat	ive Se	ecurities Beneficiall	y Owned					
1. Title of Security (Instr. 4)					nt of Securities ally Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Common Stock					3,345,849	I		See Footnote ⁽¹⁾				
		(e.ç				urities Beneficially (ptions, convertible		s)				
1. Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year)		d 3. Title and Amount of Secur Underlying Derivative Securi				rcise Form:	Ownership	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
			Date Exercisable	Expiration Date	n Title		Amount or Number of Shares	Deriva Securi	tive	or Indirect (I) (Instr. 5)		

Explanation of Responses:

1. These shares are held by Argentum Capital Partners II, L.P. (ACP II). Argentum Investments, LLC is the managing member of Argentum Partners II, LLC, which is the general partner of ACP II. Daniel Raynor is a co-managing member of Argentum Investments, LLC. Mr. Raynor disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. The business address of ACP II is 60 Madison Avenue, Suite 701, New York, NY 10010.

Remarks:

This Amendment is being filed solely to include Exhibit 24.

/s/ Roland S. Chase, as attorney-in-fact 07/29/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CONFIRMING STATEMENT

Know all by these presents, that the undersigned hereby constitutes and appoints each of Arthur S. Przybyl, Charlotte C. Arnold, Paul A. Gajer, Jane A. Meyer and Roland S. Chase (the "Authorized Signatories"), or any one or more of them, the undersigned's true and lawful attorneys-in-fact to:

- prepare and execute for and on behalf of the undersigned, in the undersigned's capacity as an officer or director of BioSante Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder, and any other forms or reports the undersigned may be required to file with the U.S. Securities and Exchange Commission in connection with the undersigned's ownership, acquisition, or disposition of securities of the Company;
- do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, or Form 3, 4, or 5, or other form or report, and timely file such form or report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of July, 2013.

/s/ Daniel Raynor
Name: Daniel Raynor